ONE-PEAK
One Peak, a leading investor for growth stage B2B software companies in Europe and Israel, is excited to announce the closing of One Peak Growth III at its hard cap of $1 billion. The fund was significantly oversubscribed, demonstrating strong LP demand. Building on the success of One Peak’s first two funds, the closing of One Peak Growth III brings the firm’s total assets under management to c. $2 billion. The size of the new fund makes One Peak, founded by David Klein and Humbert de Liedekerke Beaufort, the largest fund in Europe dedicated to backing fast growing B2B software companies in the $15m-$100m investment range.
Accelerating Growth
Humbert de Liedekerke Beaufort, Co-founder and Managing Partner, said: “Growth equity is a significantly underrepresented asset class in Europe versus the US and China. There are many world class founders in Europe who need capital and support to win at global scale, and One Peak fills that gap for the best B2B software companies. With Fund III, we’ll continue to partner with the most ambitious founders and support them with our sector expertise, global network, and value creation platform to build enduring companies against the backdrop of today’s macroeconomic headwinds. $15-100m is our investment sweet spot, where we act as a catalyst to accelerate growth and help companies realize their full potential.”
Deep B2B Sector Expertise
Over the past 8 years, One Peak has built a concentrated portfolio of minority stakes in category leading software companies such as Cymulate, Deepki, DocPlanner, PandaDoc, Neo4j, and Spryker Systems. The One Peak team is an active partner to the founders it backs and supports them in building lasting, category-defining companies for the long term. This includes access to some of the best B2B software operators in the world through One Peak’s Value Creation Team which is comprised of experts in sales, marketing, partnerships, product, tech, and talent.
David Klein, Co-founder and Managing Partner, said: “We are ultimately in the business of investing in exceptional founders, and we work alongside them with the same passion and dedication as they do. Our value-add is significantly enhanced by our fully integrated Value Creation Team, particularly when it comes to hiring the best talent, accelerating top line growth, driving global expansion, and improving product and technology capabilities. This is a key differentiator for our portfolio companies in building generational companies. Last but not least, we are grateful to our founders and LPs from around the globe for their continued trust.”
One Peak’s relationship-driven approach is augmented by PULSE, One Peak’s proprietary sourcing and business intelligence software platform. PULSE integrates with a plethora of data sources and continuously surfaces the most promising opportunities for new investments and bolt-on acquisitions for One Peak’s portfolio companies.
Strong Blue Chip Investor Base
Commitments to One Peak Growth III came from a diverse group of investors from the US and Europe, including blue chip university endowments, foundations, public pensions plans, insurance companies, asset managers, fund of funds, and family offices.
Proskauer Rose LLP and Van Campen Liem served as fund counsel to One Peak Growth III.
— Ends —
About One Peak
One Peak is a leading growth equity investment firm with approx. $2 billion in assets under management that invests in technology companies in the scale-up phase. One Peak provides growth capital, operating expertise and access to its extensive network to exceptional entrepreneurs, with a view to help transform innovative and rapidly growing businesses into lasting, category-defining leaders. One Peak’s investments include Ardoq, Brightflag, Coople, Cymulate, DataGuard, Deepki, DocPlanner, Emnify, HighQ, Infermedica, Keepit, Lucca, Neo4j, Orgvue, PandaDoc, Paysend, Quentic, Spryker Systems, and many more. To learn more, visit www.onepeak.tech.
Founder testimonials
“From the early days of our relationship, One Peak worked collaboratively with us to identify growth initiatives with the biggest impact. They helped us with revenue optimization, international expansion, M&A and the recruitment of world class talent. Above all, we really value the open and direct communication and are grateful for their trust, hard work, dedication, and passion to help us realize our vision.”
Mariusz Gralewski, Founder & CEO, DocPlanner
“One Peak has been a true value-add partner to us since day 1. They really are one of those rare investors that can zoom in and zoom out, talk big picture strategy and nitty-gritty operational details, and add value on the go-to-market side as well as challenge our thinking on product. Plus they are driven, passionate, have great clarity of thought, and are simply nice people – we genuinely enjoy the great cultural fit with the One Peak team.”
Emil Eifrem, Founder and CEO, Neo4j
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221205005103/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release
Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release
4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
Helical Fusion, Developer of Next-Generation Clean Energy Through Nuclear Fusion, Completes USD 5.5M Series A Extension Round5.12.2025 01:00:00 CET | Press release
Stakeholder base expands with participation from an individual-investor-oriented fund, alongside corporate and individual investors, bringing Total Funding to USD 38M Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; hereafter “Helical Fusion”), which is developing a next-generation energy source using Japan’s original Helical Stellarator technology to realize commercially viable fusion power plant in the 2030s, announced the completion of its Series A Extension round, raising approximately USD 5.5 million (≈ JPY 870 million). The round included investments from “Ecrowd NEXT”, a fund designed for individual investors, as well as multiple corporate investors and individual investors. As a result, Helical Fusion’s total Series A funding, including loans, amounts to approximately USD 21 million (≈ JPY 3.2 billion), bringing the company’s cumulative fundraising—including grants and loans—to approximately USD 38 million (≈ JPY 6.0 billion). With this funding, Helic
Andersen Consulting udvider sin tilstedeværelse gennem samarbejde med Hilal Technology4.12.2025 23:04:00 CET | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Hilal Technology for at styrke sine kompetencer inden for digital infrastruktur, cybersikkerhed og AI. Med tilstedeværelse i Bahrain, Saudi-Arabien, De Forenede Arabiske Emirater, Oman og Indien leverer Hilal Technology et komplet spektrum af digital infrastruktur og managed services inden for cloudcomputing, cybersikkerhed, enterprise ai og systemintegration. Deres ydelser omfatter cloudtjenester, sikkerheds- og netværksdrift, implementering af ERP og applikationer samt udvikling af generative ai-kapaciteter. Med et team på mere end 250 fagfolk servicerer firmaet en bred vifte af brancher, herunder den finansielle sektor, olie og gas, logistik og den offentlige sektor. "Transformation er mere end systemer; det handler om parathed, tillid og løbende samarbejde," udtaler Roshan George, direktør for Hilal Technology. "Vi er begejstrede for at samarbejde med Andersen Consulting og levere skalerbare løsninger, der matcher tempoet i den dig
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom